The Medical Advisor

Despite  trillions spent on cancer research  ( The Lancet Oncology ), cancer still  kills around 10 million people a year  ( WHO ) and is a leading cause of death globally, according to the World Health Organization. Cancer research continues to advance at an unprecedented pace, with new treatments offering hope to millions of patients worldwide.   Credit:  Statista Breast, lung and colon cancer are among the most common, while the number of new cancer cases annually is expected to grow by more than 75% between 2022 and 2050. As we enter 2026, several groundbreaking therapies and innovations—including personalized vaccines, gene-editing technologies, repurposed drugs, and alternative cancer treatments —are reshaping cancer care. Here are some of the most promising breakthroughs to watch for this year: 1. Next-Generation Immunotherapy Perhaps the most transformative breakthrough in modern oncology has been the rise of immunotherapy—a set of treatm...

Abstract The antiparasitic agents fenbendazole, mebendazole and ivermectin have recently emerged as promising candidates for adjunctive cancer therapy due to their multifaceted anticancer mechanisms and favorable safety profiles. Fenbendazole and mebendazole, benzimidazole derivatives, exert antitumor effects primarily through microtubule disruption and metabolic interference, inducing cell cycle arrest and apoptosis. Ivermectin, a macrocyclic lactone, complements these actions by inhibiting oncogenic signaling pathways such as STAT3, Wnt/β-catenin, and AKT/mTOR, while modulating immune responses. Recently, ivermectin has been investigated not only in dual combinations with benzimidazoles but also as part of a triple‑agent strategy involving fenbendazole and mebendazole to potentially enhance anticancer effects. Systematic reviews of publicly reported case data suggest temporal associations between this triple combination and tumor regression across diverse malignancies, although thes...